Johnson & Johnson pharma booms, medtech sinks in COVID-19-affected Q1

By Sean Whooley | April 30, 2020

Johnson & Johnson (NYSE:JNJ) shares dipped today despite first-quarter results that topped the consensus forecast.

The New Brunswick, N.J.-based company posted profits of $5.8 billion, or $2.17 per share, on sales of $20.7 billion for the three months ended March 29, 2020, for a 54.6% bottom-line gain on sales growth of 3.3%.

Get the full story at our sister site, MassDevice.

Filed Under: clinical trials, Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, Johnson & Johnson

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.